TapewireFind a company

person · Reporting owner

GORMAN KEVIN CHARLES

Disclosed activity across 2 companies

Tapewire entity
31405
SEC CIK
0001201096

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655DirectorSeptember 11, 2026September 15, 2026
Xencor IncXNCR · Entity 4487DirectorJune 16, 2026July 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEUROCRINE BIOSCIENCES INC

Report date September 11, 2026 · Filed September 15, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect525,636 Reported balance After 2026-09-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-11 · Grant · Acquired 14,343 · Balance 525,636

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

Common StockSEC Table I · non-derivativeDirect517,797 Reported balance After 2026-09-11 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2026-09-11 · Tax withholding · Disposed 7,839 · Balance 517,797

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

F3: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

F3: 517,797 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Xencor Inc

Report date June 16, 2026 · Filed July 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect21,680 Reported balance After 2026-06-16 transaction · row 1
1 source row

Row 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 21,680

F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15Direct20,604 Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604

F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.

F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 13, 2024 Filed Feb 15, 2024 22:43 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 22,415 $0.00 $0.00
Disclosure

SEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,415

Underlying: Common Stock · 22,415 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:43 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 112,644 $0.00 Strike: $133.84 $0.00
Disclosure

SEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · derivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,644

Underlying: Common Stock · 112,644 shares

Expires 2034-02-13

F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 22:43 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,832 $133.02 $376,700.46
Disclosure

SEC source: 0000914475-24-000073 · wk-form4_1708037005.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 514,596

F1 · kind: Sale of 2,832 shares of common stock issued upon vesting of 5,376 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,544) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.98 to $134.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Read SEC document
February 13, 2024 Filed Feb 15, 2024 21:02 UTC Xencor Inc XNCR · Entity 4487 PurchaseCommon Stock 53 $19.12 $1,013.36
Disclosure

SEC source: 0001127602-24-005195 · form4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,060

F1 · shares: Shares purchased by the reporting person's investment advisor in a managed account, without the knowledge of the reporting person.

Read SEC document
February 08, 2024 Filed Feb 9, 2024 00:21 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,274 $134.15 $305,052.32
Disclosure

SEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 506,962

F3 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.75 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Read SEC document
February 06, 2024 Filed Feb 9, 2024 00:21 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,040 $142.18 $432,218.38
Disclosure

SEC source: 0000914475-24-000046 · wk-form4_1707438093.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 504,919

F1 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,771 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,731) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $141.04 to $143.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2024 Filed Feb 3, 2024 00:21 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,707 $140.69 $380,844.58
Disclosure

SEC source: 0000914475-24-000028 · wk-form4_1706919702.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 502,188

F1 · kind: Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.74 to $142.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Read SEC document
January 09, 2024 Filed Jan 10, 2024 21:31 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 62,023 $19.59 Strike: $19.59 $1,215,030.57
Disclosure

SEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · derivative · entry 6

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 62,023 shares

Expires 2024-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024.

Read SEC document
January 09, 2024 Filed Jan 10, 2024 21:31 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 62,023 $134.01 $8,311,894.50
Disclosure

SEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 4

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 499,754

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.28 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Read SEC document
January 09, 2024 Filed Jan 10, 2024 21:31 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 62,023 $19.59 $1,215,030.57
Disclosure

SEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 561,777

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 21:31 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 105,835 $19.59 Strike: $19.59 $2,073,307.65
Disclosure

SEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · derivative · entry 5

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,023

Underlying: Common Stock · 105,835 shares

Expires 2024-01-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 21:31 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 105,835 $132.44 $14,016,522.81
Disclosure

SEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 499,754

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 22, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.72 to $133.94. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 08, 2024 Filed Jan 10, 2024 21:31 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 105,835 $19.59 $2,073,307.65
Disclosure

SEC source: 0000914475-24-000009 · wk-form4_1704922274.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 605,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 21, 2023 Filed Aug 24, 2023 00:08 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 9,328 $107.40 $1,001,816.01
Disclosure

SEC source: 0001209191-23-047137 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 499,754

F1 · kind: Sale of 9,328 shares of common stock issued upon vesting of 17,717 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (8,389) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4 · balance_after: 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:55 UTC Xencor Inc XNCR · Entity 4487 GrantStock Option (Right to Buy) · Derivative 10,013 $0.00 Strike: $26.19 $0.00
Disclosure

SEC source: 0001127602-23-019287 · form4.xml · derivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,013

Underlying: Common Stock · 10,013 shares

Expires 2033-06-20

F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 20, 2023, such that the total number of shares will be fully vested on June 20, 2024.

Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:55 UTC Xencor Inc XNCR · Entity 4487 GrantCommon Stock 5,007 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-019287 · form4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,007

F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:11 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 21,506 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-009886 · doc4.xml · derivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,506

Underlying: Common Stock · 21,506 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2024, February 13, 2025, February 13, 2026, and February 13, 2027.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:11 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 133,656 $0.00 Strike: $103.52 $0.00
Disclosure

SEC source: 0001209191-23-009886 · doc4.xml · derivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,656

Underlying: Common Stock · 133,656 shares

Expires 2033-02-13

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 08, 2023 Filed Feb 9, 2023 00:28 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,274 $104.30 $237,184.57
Disclosure

SEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 4

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 491,365

F8 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F9 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.72 to $105.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:28 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 20,482 $102.43 $2,098,049.09
Disclosure

SEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 489,322

F5 · kind: Sale of 20,482 shares of common stock issued upon vesting of 38,874 performance restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (18,392) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F6 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on February 7, 2023.

F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.03 to $104.00. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 00:28 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,248 $102.30 $332,265.53
Disclosure

SEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 470,930

F3 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,170 restricted stock units on February 7, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,922) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.39 to $103.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2023 Filed Feb 9, 2023 00:28 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,040 $105.68 $321,258.69
Disclosure

SEC source: 0001209191-23-007912 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 468,008

F1 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,770 restricted stock units on February 6, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.64 to $108.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 22:19 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,707 $110.08 $297,997.12
Disclosure

SEC source: 0001209191-23-006276 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 465,278

F1 · kind: Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $111.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:50 UTC Xencor Inc XNCR · Entity 4487 GrantStock Option (Right to Buy) · Derivative 21,412 $0.00 Strike: $26.58 $0.00
Disclosure

SEC source: 0001127602-22-018171 · form4.xml · derivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,412

Underlying: Common Stock · 21,412 shares

Expires 2032-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023.

Read SEC document
February 08, 2022 Filed Feb 10, 2022 00:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,274 $79.49 $180,767.54
Disclosure

SEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 4

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 462,844

F7 · kind: Sale of 2,274 shares of common stock issued upon vesting of 4,317 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,043) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $78.98 to $79.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2022 Filed Feb 10, 2022 00:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,040 $80.80 $245,630.18
Disclosure

SEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 460,801

F5 · kind: Sale of 3,040 shares of common stock issued upon vesting of 5,770 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.73 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2022 Filed Feb 10, 2022 00:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,248 $80.82 $262,517.98
Disclosure

SEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 458,071

F3 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.69 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2022 Filed Feb 10, 2022 00:00 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,422 $80.83 $195,758.63
Disclosure

SEC source: 0001209191-22-008211 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 455,150

F1 · kind: Sale of 2,422 shares of common stock issued upon vesting of 4,600 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (2,178) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 31, 2022 Filed Feb 3, 2022 00:51 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 20,565 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006580 · doc4.xml · derivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,565

Underlying: Common Stock · 20,565 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.

F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.

Read SEC document
January 31, 2022 Filed Feb 3, 2022 00:51 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 140,049 $0.00 Strike: $79.02 $0.00
Disclosure

SEC source: 0001209191-22-006580 · doc4.xml · derivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,049

Underlying: Common Stock · 140,049 shares

Expires 2032-01-31

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
June 24, 2021 Filed Jun 26, 2021 00:01 UTC Xencor Inc XNCR · Entity 4487 GrantStock Option (Right to Buy) · Derivative 9,728 $0.00 Strike: $36.01 $0.00
Disclosure

SEC source: 0001415889-21-003232 · form4-06252021_080622.xml · derivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,728

Underlying: Common Stock · 9,728 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:17 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 17,269 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-009117 · doc4.xml · derivative · entry 6

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,269

Underlying: Common Stock · 17,269 shares

Expires not disclosed

F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.

F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:17 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 103,609 $0.00 Strike: $117.63 $0.00
Disclosure

SEC source: 0001209191-21-009117 · doc4.xml · derivative · entry 5

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,609

Underlying: Common Stock · 103,609 shares

Expires 2031-02-08

F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:17 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,248 $116.71 $379,089.35
Disclosure

SEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 4

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 452,972

F7 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:17 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 4,343 $116.74 $506,999.21
Disclosure

SEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,051

F5 · kind: Sale of 4,343 shares of common stock issued upon vesting of 8,250 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (3,907) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.89 to $117.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 02:17 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,875 $116.79 $335,774.99
Disclosure

SEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,144

F3 · kind: Sale of 2,875 shares of common stock issued upon vesting of 5,770 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,895) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above.

F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 08, 2021 Filed Mar 29, 2021 10:19 UTC Amendment NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantStock Option · Derivative 113,863 $0.00 Strike: $117.63 $0.00
Disclosure

SEC source: 0001209191-21-023379 · doc4a.xml · derivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,863

Underlying: Common Stock · 113,863 shares

Expires 2031-02-08

F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Read SEC document
February 05, 2021 Filed Feb 10, 2021 02:17 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,422 $114.16 $276,504.48
Disclosure

SEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 443,249

F1 · kind: Sale of 2,422 shares of common stock issued upon vesting of 4,600 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,178) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.51 to $116.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 164,801 $8.65 Strike: $8.65 $1,425,528.65
Disclosure

SEC source: 0001209191-21-003235 · doc4.xml · derivative · entry 6

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 164,801 shares

Expires 2023-01-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Option granted January 10, 2013 and vested monthly over four years.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionNon-Qualified Stock Option · Derivative 143,449 $8.66 Strike: $8.66 $1,242,268.34
Disclosure

SEC source: 0001209191-21-003235 · doc4.xml · derivative · entry 5

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 143,449 shares

Expires 2022-01-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Option granted January 12, 2012 and vested monthly over four years.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 164,801 $110.22 $18,164,778.22
Disclosure

SEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 4

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,071

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 164,801 $8.65 $1,425,528.65
Disclosure

SEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 3

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 605,872

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 143,449 $110.21 $15,809,098.29
Disclosure

SEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 2

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,071

F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $111.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 08, 2021 Filed Jan 12, 2021 21:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 Exercise / conversionCommon Stock 143,449 $8.66 $1,242,268.34
Disclosure

SEC source: 0001209191-21-003235 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 584,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 12, 2020 Filed Nov 16, 2020 23:16 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,390 $90.78 $307,747.59
Disclosure

SEC source: 0001209191-20-058545 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,071

F1 · kind: Sale of 3,390 shares of common stock issued upon vesting of 6,440 performance restricted stock units to cover withholding taxes, with the balance of the shares (3,050) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $89.05 to $92.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 05, 2020 Filed Aug 7, 2020 23:29 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,390 $118.91 $403,101.17
Disclosure

SEC source: 0001209191-20-045753 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 438,021

F1 · kind: Sale of 3,390 shares of common stock issued upon vesting of 6,440 performance restricted stock units to cover withholding taxes, with the balance of the shares (3,050) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.16 to $120.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 25, 2020 Filed Jun 30, 2020 00:24 UTC Xencor Inc XNCR · Entity 4487 GrantStock Option (Right to Buy) · Derivative 13,953 $0.00 Strike: $33.42 $0.00
Disclosure

SEC source: 0001209191-20-039288 · doc4.xml · derivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,953

Underlying: Common Stock · 13,953 shares

Expires 2030-06-24

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021.

Read SEC document
April 24, 2020 Filed Apr 29, 2020 00:41 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 2,906 $99.45 $289,015.65
Disclosure

SEC source: 0001209191-20-026068 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,971

F1 · kind: Sale of 2,906 shares of common stock issued upon vesting of 5,520 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (2,614) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 07, 2020 Filed Feb 12, 2020 00:14 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 SaleCommon Stock 3,248 $103.35 $335,696.07
Disclosure

SEC source: 0001209191-20-008494 · doc4.xml · nonDerivative · entry 1

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 432,357

F1 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.985 to $104.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 06, 2020 Filed Feb 7, 2020 23:44 UTC NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 GrantRestricted Stock Unit · Derivative 23,081 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-007681 · doc4.xml · derivative · entry 5

GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,081

Underlying: Common Stock · 23,081 shares

Expires not disclosed

F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024.

F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.